Sionna Therapeutics Phase 2a Trial Failure
Analysis based on 30 articles · First reported Aug 12, 2026 · Last updated Sep 03, 2026
The failed trial wiped out over 90% of Sionna's market value in a single session, severely impacting shareholders and triggering multiple securities investigations. The event highlights the high-risk nature of clinical-stage biopharmaceutical investments and may lead to legal liabilities for the company.
On August 10, 2026, Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719, an investigational cystic fibrosis treatment, failed to achieve its key activity endpoint of sweat chloride reduction when added to standard-of-care Trikafta. The placebo-adjusted sweat chloride change was -1.0 mmol/L with a p-value of 0.7, and the company stated it would not advance SION-719 as an add-on therapy. Following the disclosure, Sionna's stock price plummeted 91.18%, falling $46.54 to close at $4.50 per share, erasing approximately 92% of the company's market value. The company reported $268.3 million in cash and equivalents as of June 30, 2026, with a Q2 net loss of $29.9 million and runway into 2028. In response, multiple law firms, including Pomerantz LLP, Levi & Korsinsky, and Robbins Geller Rudman & Dowd LLP, launched investigations into potential securities fraud or unlawful business practices by Sionna and certain officers and directors, focusing on statements made before the trial results were disclosed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard